Talecris Biotherapeutics Prices Initial Public Offering of Common Stock at $19.00 Per Share

Talecris Biotherapeutics Prices Initial Public Offering of Common Stock at $19.00 Per Share

Research Triangle Park, N.C. (September 30, 2009) - Talecris Biotherapeutics Holdings Corp. ("Talecris" or the "Company") today announced the pricing of its initial public offering of 50,000,000 shares of its common stock at a price of $19.00 per share.  Of the shares being offered, 28,947,368 are being offered by the Company and 21,052,632 are being offered by the selling stockholder, Talecris Holdings, LLC.  Talecris Holdings, LLC is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and limited partnerships affiliated with Ampersand Ventures.  The underwriters have the option to purchase from the selling stockholder up to an additional 6,000,000 shares of common stock.  The common stock is expected to begin trading on the Nasdaq Stock Market LLC on October 1, 2009 under the ticker symbol "TLCR."

Talecris intends to use the net proceeds of the offering to repay amounts owed under its First Lien Term Loan Credit Agreement and Second Lien Term Loan Credit Agreement.  Talecris will not receive any of the proceeds from the offering of the common stock by the selling stockholder.

Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co., Citigroup Global Markets Inc. and J.P. Morgan Securities Inc. are acting as joint book-running managers for the offering.  Wells Fargo Securities, LLC, Barclays Capital Inc. and UBS Investment Bank are acting as co-managers.  Reed Smith LLP acted as legal counsel to Talecris.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 30, 2009.  This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any such offer or solicitation or any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

The offering of these securities will be made only by means of a prospectus, copies of which may be obtained by contacting:  Morgan Stanley & Co. Incorporated, Attention: Prospectus Department, 180 Varick Street, New York, New York 10014, telephone 1-866-718-1649 or by emailing [email protected]; Goldman, Sachs & Co., Prospectus Department, 85 Broad Street, New York, New York 10004, telephone 1-866-471-2526, facsimile 1-212-902-9316 or by emailing [email protected]; Citigroup Global Markets Inc. at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, New York 11220, telephone 1-800-831-9146; or J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, Attention: Prospectus Department, telephone 718-242-8002.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology and hemostasis.

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.